NTRK1 and neuroblastoma: ALKA-372-001 phase I Trial showed that Entrectinib has a significant antitumor response in TrkA-positive CRC, ALK-rearranged neuroblastoma, and ROS1-, or ALK-positive NSCLC patients [155].